BR112022013488A2 - Pirazolo-pirimidinas substituídas e seu uso - Google Patents
Pirazolo-pirimidinas substituídas e seu usoInfo
- Publication number
- BR112022013488A2 BR112022013488A2 BR112022013488A BR112022013488A BR112022013488A2 BR 112022013488 A2 BR112022013488 A2 BR 112022013488A2 BR 112022013488 A BR112022013488 A BR 112022013488A BR 112022013488 A BR112022013488 A BR 112022013488A BR 112022013488 A2 BR112022013488 A2 BR 112022013488A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidines
- substituted pyrazolo
- compounds
- treatment
- pikfyve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PIRAZOLO-PIRIMIDINAS SUBSTITUÍDAS E SEU USO. A presente invenção refere-se a compostos que são inibidores das PIKfyve cinases úteis para o tratamento de doenças neurológicas tratáveis através da inibição de PIKfyve. Também são fornecidas composições farmacêuticas contendo tais compostos e métodos de tratamento utilizando tais compostos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062960412P | 2020-01-13 | 2020-01-13 | |
US202063074388P | 2020-09-03 | 2020-09-03 | |
PCT/US2021/013077 WO2021146192A1 (en) | 2020-01-13 | 2021-01-12 | Substituted pyrazolo-pyrimidines and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022013488A2 true BR112022013488A2 (pt) | 2022-09-13 |
Family
ID=74626126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022013488A BR112022013488A2 (pt) | 2020-01-13 | 2021-01-12 | Pirazolo-pirimidinas substituídas e seu uso |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230133203A1 (pt) |
EP (1) | EP4090426A1 (pt) |
JP (1) | JP2023510874A (pt) |
KR (1) | KR20220140515A (pt) |
CN (1) | CN115209952A (pt) |
AU (1) | AU2021207804A1 (pt) |
BR (1) | BR112022013488A2 (pt) |
CA (1) | CA3167339A1 (pt) |
CL (1) | CL2022001887A1 (pt) |
CO (1) | CO2022011258A2 (pt) |
IL (1) | IL294504A (pt) |
MX (1) | MX2022008627A (pt) |
TW (1) | TW202140483A (pt) |
WO (1) | WO2021146192A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022256300A1 (en) * | 2021-06-01 | 2022-12-08 | Verge Analytics, Inc. | Fused bicyclic heterocyclic compounds and uses thereof |
WO2024014885A1 (ko) * | 2022-07-13 | 2024-01-18 | 일동제약(주) | 신규 바이사이클릭 헤테로아릴 화합물 및 이의 용도 |
WO2024168016A1 (en) * | 2023-02-10 | 2024-08-15 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3696884B2 (ja) | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO2016210372A2 (en) | 2015-06-25 | 2016-12-29 | University Of Southern California | Methods to treat neurological diseases |
EP3600328A4 (en) * | 2017-03-24 | 2021-01-06 | 3100 Central Expressway LLC | MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION |
US20200199136A1 (en) * | 2017-08-28 | 2020-06-25 | Acurastem Inc. | Pikfyve kinase inhibitors |
AU2019299234A1 (en) * | 2018-07-05 | 2021-01-14 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
-
2021
- 2021-01-12 CN CN202180018763.7A patent/CN115209952A/zh active Pending
- 2021-01-12 US US17/792,304 patent/US20230133203A1/en active Pending
- 2021-01-12 JP JP2022542901A patent/JP2023510874A/ja active Pending
- 2021-01-12 WO PCT/US2021/013077 patent/WO2021146192A1/en active Application Filing
- 2021-01-12 MX MX2022008627A patent/MX2022008627A/es unknown
- 2021-01-12 KR KR1020227027606A patent/KR20220140515A/ko unknown
- 2021-01-12 AU AU2021207804A patent/AU2021207804A1/en active Pending
- 2021-01-12 IL IL294504A patent/IL294504A/en unknown
- 2021-01-12 TW TW110101124A patent/TW202140483A/zh unknown
- 2021-01-12 CA CA3167339A patent/CA3167339A1/en active Pending
- 2021-01-12 EP EP21705700.9A patent/EP4090426A1/en active Pending
- 2021-01-12 BR BR112022013488A patent/BR112022013488A2/pt unknown
-
2022
- 2022-07-12 CL CL2022001887A patent/CL2022001887A1/es unknown
- 2022-08-10 CO CONC2022/0011258A patent/CO2022011258A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230133203A1 (en) | 2023-05-04 |
AU2021207804A1 (en) | 2022-09-01 |
WO2021146192A1 (en) | 2021-07-22 |
KR20220140515A (ko) | 2022-10-18 |
CL2022001887A1 (es) | 2023-04-10 |
CN115209952A (zh) | 2022-10-18 |
CO2022011258A2 (es) | 2022-09-30 |
JP2023510874A (ja) | 2023-03-15 |
CA3167339A1 (en) | 2021-07-22 |
EP4090426A1 (en) | 2022-11-23 |
IL294504A (en) | 2022-09-01 |
TW202140483A (zh) | 2021-11-01 |
MX2022008627A (es) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022000064A2 (pt) | Inibidores de hpk1 e usos dos mesmos | |
BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
BR112021020637A2 (pt) | Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia | |
BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
BR112015015635A8 (pt) | composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão | |
UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
BR112019018648A2 (pt) | Inibidores de jak contendo uma amida heterocíclica com 4 membros | |
BR112015021999A8 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase | |
BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
CL2023002223A1 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
BR112022025117A2 (pt) | 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 | |
AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
CL2022003329A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
BR112023015425A2 (pt) | Derivados de uracila como inibidores de trpa1 | |
AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
DOP2022000270A (es) | Derivados de tetrazol como inhibidores de trpa1 | |
CO2023000858A2 (es) | Inhibidores de atr y usos de estos | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 |